The Office of Information and Regulatory Affairs (OIRA) recently updated its dashboard to disclose that the SEC had submitted a rulemaking titled “Rescission of Climate-Related Disclosure Rules” for review.

O​n November 8, 2023, the CFPB and a national bank entered into a consent order​ to resolve allegations that the bank engaged in intentional discrimination against Armenian Americans...

On August 3, 2022, the California Department of Financial Protection and Innovation (DFPI) announced ​that it had entered into a consent order with a Florida-based lending company that...

On November 17, 2025, the California Department of Financial Protection and Innovation (DFPI) announced that it had entered into consent order with a California-based lender to resolve allegations that the lender charged excessive interest and fees to its customers.

On July 27, 2022, the Consumer Financial Protection Bureau (CFPB) and U.S. Department of Justice (DOJ) filed a complaint and proposed consent order in...

The Consumer Financial Protection Bureau (CFPB) announced that it filed a complaint against a banking-as-a-service platform on August 21, 2025 in the U.S. Bankruptcy Court...

On December 1, 2022 the Consumer Financial Protection Bureau (CFPB) announced that it had reached a proposed settlement ​with a Delaware-based financial services company to resolve allegations...

The Consumer Financial Protection Bureau ("CFPB") filed a complaint against a manufactured home loan company (the "Company") on January 6, 2025, alleging that it originates loans that borrowers...

In August, the Federal Deposit Insurance Corporation (FDIC) approved the deposit insurance application of Augustus National Bank, N.A., a newly chartered national bank that focuses on deposit and lending products for digital asset companies, technology companies, and artificial intelligence companies, as well as offering virtual currency, payment, and treasury services.

Two recent notices issued by the Internal Revenue Service (the "IRS") and the U.S. Treasury Department’s Financial Crimes Enforcement Network ("FinCEN") have extended the deadline for filing Form TD F 90-22.1, Report of Foreign Bank and Financial Accounts ("FBAR") by certain individuals with signature authority over, but no financial interest in, foreign financial accounts.

On May 22, 2024,​ the Massachusetts Attorney General (MA AG) announced it entered into an Assurance of Discontinuance (AOD) with a California-based financing company resolving allegations...

On November 23, 2021, New York Attorney General Letitia James ("New York AG") announced that her office entered into an agreement with a debt collection company to resolve allegations that the...

On August 18, 2025, Accord BioPharma, Inc. ("Accord BioPharma") announced the commercial launch of IMULDOSA® (ustekinumab-srlf), a biosimilar to STELARA® (ustekinumab)...

We previously reported that South Korean biopharmaceutical company Alteogen submitted its Marketing Authorization Application to the European Medicines Agency ("EMA") for ALT-L9...

Under the terms of the agreement, Alvotech will receive exclusive global rights for AVT23 and BiosanaPharma will receive an upfront payment and will be eligible for certain tiered royalties.

Alvotech and Lotus Pharmaceutical have entered into a strategic licensing and commercialization agreement for two proposed biosimilars targeting major therapeutic markets. The deal encompasses semi-exclusive U.S. rights and exclusive rights across eight Asian markets, with Alvotech retaining development and regulatory responsibilities. Financial terms include potential payments of up to $150 million plus ongoing supply revenue.

Alvotech and Stada recently announced the launch of HUKYNDRA® to patients in certain European countries, including France, Germany, Finland, and Sweden.

On April 23, 2024, Alvotech announced "positive topline results from a confirmatory clinical study for AVT05," Alvotech's proposed golimumab biosimilar to Janssen Biotech, Inc.'s...

On August 23, 2022, Amgen announced positive top-line results from a phase 3 study of ABP 959, Amgen's proposed biosimilar to SOLIRIS.

Amneal announced today that the U.S. Food and Drug Administration has approved its Biologics License Application for FYLNETRA™ (pegfilgrastim-pbbk), a biosimilar referencing NEULASTA®.